Home Featured Page 34

Featured

Latest

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It

Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression

July 2025 Psychedelic Patent Update

Dr Case Newsom – Creating Safe Spaces: The Zendo Project’s Approach...

The Psychedelics & Pain Symposium 2025

Growing Attention To Psychedelics For Pain, Physical & Neurological Conditions

Kat Murti – Students for Sensible Drug Policy, Meta Censorship, and...

Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum...

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It

Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression

July 2025 Psychedelic Patent Update

Dr Case Newsom – Creating Safe Spaces: The Zendo Project’s Approach...

The Psychedelics & Pain Symposium 2025

Growing Attention To Psychedelics For Pain, Physical & Neurological Conditions

Kat Murti – Students for Sensible Drug Policy, Meta Censorship, and...

Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum...

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

EDITOR PICKS

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY